Lilly says experimental obesity drug delivered weight loss across all stages of menopause (LLY:NYSE)
Post-hoc analyses found up to 51.5% of women reached at least 15% weight loss, with waist size also falling across menopausal stages.
- Yesterday, Eli Lilly and Company announced that Foundayo demonstrated significant weight loss in women across all menopausal stages during the ATTAIN-1 and ATTAIN-2 clinical trials.
- Hormonal changes during menopause accelerate fat accumulation, particularly around the abdomen, making weight loss harder to achieve and sustain, according to Dr. Rachel Batterham, Lilly senior vice president of medical innovation and external engagement.
- In ATTAIN-1, perimenopausal women lost up to 30.4 lbs and post-menopausal participants lost up to 28.2 lbs on the highest dose of Foundayo at 72 weeks.
- Researchers presented these findings, based on post-hoc analyses of more than 1,500 female participants, at the American Diabetes Association 86th Scientific Sessions.
- Foundayo is a once-daily oral GLP-1 receptor agonist taken without food or water restrictions, positioning the medication as a potential chronic weight management option for women across menopausal stages.
28 Articles
28 Articles
Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages - Eli Lilly (NYSE:LLY)
Eli Lilly and Co. (NYSE:LLY) on Sunday presented new analyses showing that women with obesity or overweight achieved significant weight loss with Foundayo across all stages of menopause. The findings were based on post-hoc analyses involving more than 1,500 women enrolled in the ATTAIN-1 and ATTAIN-2 clinical trials and were presented at the American Diabetes Association’s 86th Scientific Sessions. data-variant="card" data-news-mode="manual" > …
LoudounTimes.com
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)
Eli Lilly stock rises as Retatrutide data boosts obesity drug lead
Shares of Eli Lilly LLY climbed about 4% on Monday after the drugmaker unveiled encouraging new clinical data for its next-generation obesity treatment, retatrutide.This has reinforced investor confidence in the company's long-term position in the rapidly expanding weight-loss market.The latest results were presented at the American Diabetes Association's annual Scientific Sessions in New Orleans, where Lilly released full data from two late-sta…
Coverage Details
Bias Distribution
- 53% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
